PoliticalRepoPoliticalRepo

Person

Official portrait of John Curtis

John Curtis

United States · Official source

Records

1,131 records where John Curtis is listed as a sponsor, author, or other actor. Search with topics and years

Bill· SS. 5181 (119th)referred

MAP Roads Act

United States · United States Congress · 30 July 2026

Bill· SS. 5114 (119th)referred

PATH Act

United States · United States Congress · 23 July 2026

Bill· SS. 5025 (119th)referred

Lindsey O. Graham Sanctioning Russia Act of 2026

United States · United States Congress · 16 July 2026

Lindsey O. Graham Sanctioning Russia Act of 2026 This bill imposes a variety of sanctions, tariffs, and prohibitions related to Russia. For example, under the bill, the President must  impose visa- and property-blocking sanctions on specified persons (individuals and entities) such as the Russian president, certain Russian military commanders, and any foreign person that knowingly provides goods or services relating to Russia's defense industrial base; increase the rate of duty on all goods imported into the United States from Russia to a rate of up to 500% ad valorem (i.e., relative to the value); increase the rate of duty up to 100% ad valorem on all goods imported into the United States from a country that was among the five largest importers of Russian-origin crude oil and natural gas if such country knowingly makes new purchases of such products after enactment of the bill; impose property-blocking sanctions on financial institutions organized under Russian law and owned wholly or partly by Russia; and  impose property-blocking sanctions on foreign vessels that knowingly transport certain products of Russian origin, including crude oil, uranium, and coal.  The bill prohibits (1) the export, reexport, or in-country transfer to or in Russia of U.S.-produced energy or energy product; (2) U.S. persons from making new investments in Russia or purchasing Russian sovereign debt; and (3) trading the securities of Russian government-owned, -controlled, or -affiliated entities on U.S. national securities exchanges. The President may waive requirements of the bill by certifying it is in the national interest.

Bill· SS. 4967 (119th)referred

Stop TNR Act of 2026

United States · United States Congress · 14 July 2026

Resolution· SRESS.Res. 791 (119th)referred

A resolution condemning the People's Republic of China's Ethnic Unity and Progress Law, concerned with its implications on the rights and freedoms, as well as survival of the identity, of Tibetans, Uyghurs, Mongolians, and other affected communities, and calling on the Government of the People's Republic of China to end its abuses and campaigns of transnational repression that undermine United States sovereignty and threaten the safety and freedoms of people in the United States.

United States · United States Congress · 24 June 2026

This resolution condemns a Chinese law, known as the Ethnic Unity and Progress Law, for institutionalizing coercive assimilation of ethnic and religious minorities. The resolution also calls on the President to consider related sanctions and urges the Department of State to work with allies to monitor and report on the impacts of the law.

Bill· SS. 4855 (119th)referred

SAFE KIDS Act

United States · United States Congress · 23 June 2026

Bill· SS. 4844 (119th)referred

PFAS Alternatives Act

United States · United States Congress · 18 June 2026

Bill· SS. 4610 (119th)open

Pacific POWER Act

United States · United States Congress · 20 May 2026

Bill· SS. 4561 (119th)open

CLOSE THE GAP Act

United States · United States Congress · 19 May 2026

Bill· SS. 4555 (119th)referred

GAME Act of 2026

United States · United States Congress · 18 May 2026

Bill· SS. 4472 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 30 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs. Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements. Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.